Sanofi’s Sarclisa gains new US multiple myeloma indication
pharmaphorum
APRIL 1, 2021
This label extension covers use of Sarclisa plus carfilzomib and dexamethasone for adults with relapsed or refractory multiple myeloma, who have received one to three previous therapy lines. In the trial, 8% of patients dropped out because of adverse events and 2.8% quit because of an infection.
Let's personalize your content